Clarivate Epidemiology's coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and Europe and 10 years for the other countries covered in this report.
Clarivate Epidemiology's PsO forecast will answer the following questions:
Of all people diagnosed with PsO, how many in each country across the developed world are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PsO over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 11 PsO patient populations, as follows:
Literature review (studies included in / excluded from the analyses of psoriasis)
Diagnosed prevalent cases
Diagnosed prevalent cases by severity
Diagnosed Drug-Treated Prevalent Cases by Severity
Diagnosed prevalent cases by subtype
Risk / protective factors applied to disease forecast models
Reference materials
Bibliography
Glossary
Abbreviations
Navya Vardhan
Navya Vardhan, M.Sc., Epidemiologist, Epidemiology. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.
Stephanie Niquita Phankon
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.
